Overview

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Status:
Completed

Trial end date:
2019-02-15

Target enrollment:

Participant gender:

Summary

This will be a single center, phase 1, open-label, fixed-sequence study under fasting conditions to evaluate the effect of 90 mg intravenous (IV) infusions of GC4419 on the single-dose pharmacokinetic (PK) of dextromethorphan (DM) capsules liquid filled.

Phase:

Phase 1

Details

Lead Sponsor:

Galera Therapeutics, Inc.

Treatments:

Avasopasem manganese
Dextromethorphan